Back to Course

Managing ADHD Medication Adverse Events

0% Complete
0/20 Steps

Emergencies and Urgent Stops 

Common Side Effects: Adjust the Regimen

Non-Stimulant Safety Problems

Misuse, Interactions and Restarts

Rapid Triage Summary

    • Emergencies and Urgent Stops 
      • Stimulant Overdose or Accidental Ingestion: When Is Emergency Evaluation Needed?
      • Guanfacine, Clonidine or Other Non-Stimulant Overdose or Accidental Ingestion: When Is Emergency Evaluation Needed?
      • New Psychosis or Mania During ADHD Treatment: When to Stop and Can You Rechallenge?
      • Chest Pain, Palpitations or Syncope During ADHD Treatment: When to Stop and Refer Urgently?
      • Rebound Hypertension After Stopping Guanfacine or Clonidine: How Urgently to Act?
    • Common Side Effects: Adjust the Regimen
      • Appetite Suppression, Weight Loss and Growth on ADHD Medication: When to Adjust Treatment?
      • Insomnia After ADHD Medication: Change Timing, Dose or Formulation?
      • Anxiety or Panic on a Stimulant: Reduce, Change or Stop?
      • Irritability, Wear-Off Rebound or Emotional Blunting: How Should the Stimulant Change?
      • Nausea, Abdominal Pain, Constipation or Headache on ADHD Medication: Adjust or Investigate?
    • Non-Stimulant Safety Problems
      • Suicidal Thinking on Atomoxetine or Viloxazine: Continue, Reduce or Stop?
      • Sedation, Dizziness, Hypotension or Bradycardia on a Non-Stimulant: Reduce, Retitrate or Switch?
      • Urinary or Sexual Adverse Effects on Atomoxetine: Reduce, Evaluate or Switch?
    • Misuse, Interactions and Restarts
      • Suspected Misuse, Diversion or Substance-Use Relapse: Continue, Restrict or Stop?
      • Uncommon Serious Reactions to ADHD Medication: Which Need Immediate Evaluation or Stopping?
      • Suspected Drug-Interaction Toxicity: Which Medication to Hold or Stop?
      • Adverse Effects After Missed Doses, Restarting or Switching Formulations: When to Retitrate?
    • Rapid Triage Summary
      • ADHD Medication Adverse Events: Rapid Triage, Dose Changes and Stopping Rules
Lesson 11 of 20
In Progress

New or Worsening Tics During Stimulant Treatment: Continue, Reduce or Switch?

  • You must enroll in this course to access course content.

ADHD Medication Adverse Events · Section 2 · Chapter 11 · Tics

New or Worsening Tics During Stimulant Treatment: Continue, Reduce or Switch?

A boy starts blinking hard a month after his methylphenidate dose went up. A girl with Tourette's syndrome needs ADHD treatment, and her parents fear it will make the tics worse. Tics are common in children with ADHD, and they come and go on their own, which makes it hard to tell whether the stimulant is to blame. This chapter covers what the labels say, how to judge whether the stimulant is responsible, and when to continue, reduce, switch or stop.

Bedside panel ~2 min Detailed chapter ~12 min Updated Oct 2026

The 30-second version

  1. What the labels report. Every stimulant label reviewed here warns that stimulants have been associated with the onset or worsening of motor and verbal tics, and that worsening of Tourette's syndrome has been reported. The labels ask prescribers to assess family history and examine for tics before starting, to monitor for them, and to stop treatment if clinically appropriate. In label trials, tic was reported in 7.1% of children on the methylphenidate patch against 0% on placebo, and in 2% of children aged 6 to 12 on lisdexamfetamine against 0%.
  2. Is it the stimulant? NICE asks prescribers to think about whether the tics are related to the stimulant, noting that tics naturally wax and wane, and whether the impairment from the tics outweighs the benefit of ADHD treatment. In a meta-analysis of 22 placebo-controlled trials in 2,385 children, new or worse tics were reported in 5.7% on stimulants and 6.5% on placebo (risk ratio 0.99; abstract only). Our view: timing after a start or dose increase, family history and the course over several weeks help decide.
  3. Reduce, switch or stop. If tics are related to the stimulant, NICE says to reduce the stimulant dose, or consider changing to guanfacine (children and young people), atomoxetine or clonidine (children, only after advice from a tertiary ADHD service), or stopping medication. In the US, guanfacine ER and clonidine ER are also approved as add-ons to a stimulant for ADHD (not for tics). Our view: reduce first, and change one thing at a time.
  4. Known tic disorder. NICE says to offer people with ADHD and a tic disorder the same medication choices as other people with ADHD. A Cochrane review found that stimulants have not been shown to worsen tics in most people with tic disorders, though they may in individual cases; the evidence was of low or very low quality. For people with tics who have access to it, the American Academy of Neurology says to offer behavioral therapy (CBIT) as an initial treatment option relative to medication.
  5. Movements that may not be tics. Our view: tics causing injury, or movements that may be seizures or another movement disorder, need same-day assessment. NICE says to review ADHD medication if seizures are new or worse, and to stop any medication that might be contributing. Rapid onset of complex tic-like movements and sounds in an adolescent may be functional rather than a primary tic disorder. Extra or unaccounted-for doses are also a same-day flag (Chapters 1 and 16).

At the visit: tics on a stimulant

About 2 min to read · the detailed chapter follows below

Do now

  1. Ask when the tics began, against the start date and dose changes.
  2. Ask whether there were tics before treatment, and in the family.
  3. Ask how much the tics interfere, from the patient's and family's view.
  4. Watch the movements yourself, or ask for a phone video.
  5. Record tic type and severity, and repeat at each visit.

Do not

  • Stop a helpful stimulant for mild tics without weighing the benefit (NICE).
  • Change the dose and the drug at the same visit.
  • Start clonidine for tics in a child without tertiary advice (NICE, UK guidance).
  • Assume every jerk or stare is a tic.
  • Stop guanfacine or clonidine abruptly (Chapter 5).

Five questions to ask

  1. When did the tics start? Before treatment, after starting, or after a dose increase.
  2. Has anyone in the family had tics? The labels ask about this before starting.
  3. How much do the tics interfere? The AAN asks clinicians to judge this from the patient's and caregiver's view.
  4. How much has the ADHD improved? NICE weighs one against the other.
  5. Are these typical tics? Tics are usually brief and rapid, often preceded by an urge, and older children can usually hold them back briefly [14][15].
New or worse tics on ADHD medicineEstablish when they began against the dose, the family history, how much they interfere, and how much the ADHD has improved
▼

Emergency or same day if any of

  • Possible seizure in progress, or injury needing urgent care: emergency care now (call 911)
  • Tics causing injury or pain
  • Movements that may be seizures or another movement disorder rather than tics (our view)
  • Extra or unaccounted-for doses: if an overdose is possible, contact Poison Control (1-800-222-1222) or seek emergency care now (Chapters 1 and 16)
▼ none of these

Reduce the dose or switch if

  • Tics appear related to the stimulant and their impairment outweighs the benefit of treatment (NICE)
▼ none of these

Continue and monitor

Mild tics with a clear benefit from ADHD treatment: continue, record tic severity over several weeks, and explain that tics naturally wax and wane (NICE); watchful waiting is acceptable when tics do not impair (AAN guideline for Tourette's and chronic tic disorders).

Prescriber-side triage for tics on ADHD medicine. Our synthesis of the US labels [1][2][3][4][5][6][7][8], NICE NG87 [11] and the American Academy of Neurology guideline [16], not a validated instrument.

Why it gets missed or overcalled

  • Tics come and go on their own (NICE) [11]
  • In one cohort, tics began at a mean age of 5.6 years and were worst at about 10 (abstract only) [17]
  • Older children can usually hold tics back briefly [15], so they may not be seen in clinic (our view)
  • Pre-treatment tics are not recorded

Match the change to the picture

  • Mild, ADHD better: continue and monitor
  • Related and impairing: reduce, switch or stop (NICE)
  • Our order: reduce first, then switch or add
  • Not typical tics: assess the same day

Look up the situation

Tap the situation for what it means and what to do.

Emergency or same day

Reduce or switch

Continue and monitor

Tics causing injury or pain

Urgent

In Tourette’s and chronic tic disorders, the AAN says physicians may consider deep brain stimulation for "severe, self-injurious tics, such as severe cervical tics that result in spinal injury", but only after several medication classes and behavioral therapy have been tried or are contraindicated (recommendations 13d and 13e) [16]. This is not guidance for new tics. Our view: tics causing injury or pain need same-day assessment, urgent care for significant injury, and specialist evaluation for severe or persistent tics.

What to do

  • Injury needing urgent care: emergency care now; otherwise assess the same day (our view)
  • Reduce or hold the stimulant while assessed (our view)

Keep in mind

  • Labels: stop treatment if clinically appropriate [1][7]
  • Refer to a tic or movement disorder specialist (our view)

Movements that may not be tics

Same day

NICE: if seizures are new or worse, review ADHD medication and stop any medication that might be contributing; after investigation, cautiously reintroduce ADHD medication if it is unlikely to be the cause [11].

What to do

  • Same-day assessment for staring spells, jerks with loss of awareness, or sustained abnormal postures (our view)
  • Ask for a phone video (our view)

Keep in mind

  • Typical tics are brief and rapid, and often preceded by an urge [14]
  • Rapid-onset complex tic-like behaviors in adolescent girls may be functional (expert viewpoint) [15]

New, impairing tics after a start or dose increase

Weigh

NICE: think about whether the tics are related to the stimulant (tics naturally wax and wane) and whether the impairment from the tics outweighs the benefit of ADHD treatment [11].

What to do

  • If related and impairing, reduce the dose [11]
  • If mild, continue and record severity for several weeks (our view)

Keep in mind

  • Meta-analysis: new or worse tics in 5.7% on stimulants against 6.5% on placebo (abstract only) [18]
  • Label: tic 7.1% against 0% on the methylphenidate patch (children) [4]

Known tic disorder: worsening tics that impair

Weigh

NICE: offer people with ADHD and a tic disorder the same medication choices as other people with ADHD [11]. The labels note that worsening of Tourette's syndrome has been reported [1][7].

What to do

  • Compare with the tic pattern before treatment (our view)
  • Reduce the dose if the worsening follows the stimulant [11]

Keep in mind

  • Cochrane: stimulants may worsen tics in individual cases, and tics may limit dose increases [19]
  • AAN: where available, offer CBIT as an initial treatment for tics [16]

Still impairing after a dose reduction

Switch

NICE: consider changing to guanfacine (children aged 5 and over and young people only), atomoxetine, clonidine (children; only after advice from a tertiary ADHD service), or stopping medication [11].

What to do

  • Choose one alternative and change one thing at a time (our view). On guanfacine or clonidine, monitor heart rate and blood pressure and counsel about sedation; on guanfacine ER, monitor QTc with cardiac history, another QT-prolonging drug or a family history of long QT [16]
  • Taper guanfacine or clonidine if later stopped [16]; Chapter 5

Keep in mind

  • Atomoxetine did not worsen tics in a trial in 148 children with ADHD and tic disorders [8]
  • Guanfacine in three daily doses: tic severity fell 31% against 0% in 34 children with ADHD and tics (abstract only) [20]; a guanfacine ER pilot found no meaningful effect on tics [21]

Mild tics, ADHD much better

Continue

NICE asks whether the impairment from the tics outweighs the benefit of ADHD treatment, and notes that tics naturally wax and wane [11]. The AAN guideline for Tourette's and chronic tic disorders says watchful waiting is acceptable when tics cause no functional impairment [16].

What to do

  • Continue, and record tic severity at each visit (our view)
  • Explain to the family and school what tics are (our view)

Keep in mind

  • Peak tic severity usually occurs at ages 10 to 12, and many children improve in adolescence [16]
  • AAN: a valid scale may be used to measure tic severity [16]
The three tiers on one page (figure)
Emergency or same day Red flags Tics causing injury Possible seizure Other movements Chapters 1, 16: doses Reduce or switch Related, impairing Reduce the dose Or switch (NICE) Or add alpha-2 for ADHD One change at a time Continue and monitor Mild, ADHD better Tics wax and wane Log tics for weeks Same drugs if Tourette's Weigh tics vs benefit

Figure 1. Tics on a stimulant: when to seek emergency care or assess the same day, when to reduce or switch, and when to continue and monitor. Extra or unaccounted-for doses are also a same-day flag in the triage (Chapters 1 and 16). Our summary of the US labels, NICE NG87 and the American Academy of Neurology guideline [1][7][11][16].

What the labels report

Every stimulant label reviewed here warns that stimulants have been associated with the onset or worsening of motor and verbal tics, and that worsening of Tourette's syndrome has been reported. The labels ask prescribers to assess family history and examine for tics before starting, to monitor for them, and to stop treatment if clinically appropriate. In label trials, tic was reported in 7.1% of children on the methylphenidate patch against 0% on placebo, and in 2% of children aged 6 to 12 on lisdexamfetamine against 0%.

DrugTics in the labelSource
Methylphenidate patch (Daytrana)Children: tic 7.1% against 0%; tics led to stopping in 1%. Adolescents: no tics reported in either group5.15; 6.1, Table 2 [4]
Lisdexamfetamine (Vyvanse)Ages 6 to 12: tic 2% against 0%5.8; 6.1, Table 1 [7]
OROS-methylphenidate (Concerta), Ritalin, Focalin XRWarning on tics and Tourette's syndrome; check family history and examine before starting; monitor; stop if clinically appropriate5.11 [1]; 5.10 [2]; 5.10 [3]
Mixed amphetamine salts (Adderall XR, Adderall)Same warning; motor and verbal tics among postapproval reports5.9; 6.2 [6]; warnings [5]
Atomoxetine (Strattera)Did not worsen tics in an 18-week trial in 148 children with ADHD and Tourette's syndrome or chronic motor tic disorder; tics in postmarketing reports14.3; 6.2 [8]
Guanfacine ER, clonidine ER, viloxazineWe found no tic warning in these labels. Guanfacine ER and clonidine ER are approved for ADHD (not for tics), alone or as add-ons to a stimulant[9][10][12]
The detail: what the labels do and do not tell you

The tic warning is class wording: "CNS stimulants, including methylphenidate, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette's syndrome has also been reported" [2]. Each stimulant label asks prescribers to assess the family history and clinically evaluate patients for tics or Tourette's syndrome before starting, to monitor regularly for emergence or worsening, and to discontinue treatment if clinically appropriate [1][2][3][4][5][6][7]. The patient labeling asks patients to tell the prescriber if they "have or had repeated movements or sounds (tics) or Tourette's syndrome, or have a family history of tics or Tourette's syndrome" [1][7]. Only two pediatric trial tables report tic as a separate row: the methylphenidate patch (7 of 98 children against 0 of 85) and lisdexamfetamine (2% against 0%) [4][7]. These are short trials, so they cannot show whether the tics would have appeared anyway, or how long they lasted. Pooled placebo-controlled data are covered in the next section.

Reduce, switch or stop

If tics are related to the stimulant, NICE says to reduce the stimulant dose, or consider changing to guanfacine (children and young people), atomoxetine or clonidine (children, only after advice from a tertiary ADHD service), or stopping medication. In the US, guanfacine ER and clonidine ER are also approved as add-ons to a stimulant for ADHD (not for tics). Our view: reduce first, and change one thing at a time.

OptionWhat we can sayBasis
Reduce the stimulant doseFirst option in NICE's listNICE 1.8.14 [11]
GuanfacineChildren aged 5 and over and young people only. In 34 children with ADHD and tics, ADHD scores improved 37% against 8% and tic severity 31% against 0%. With guanfacine ER, the AAN says prescribers must monitor QTc when there is cardiac history, another QT-prolonging drug or a family history of long QT (Level A)NICE 1.8.14 [11]; trial, abstract only [20]; AAN 8e [16]
AtomoxetineDid not worsen tics in 148 children with ADHD and tic disorders (18 weeks). Off-label in NICE's terms for adults with no ADHD symptoms in childhood14.3 [8]; NICE 1.8.14 [11]
ClonidineNICE (UK): off-label for children, and only after advice from a tertiary ADHD service. In the US, clonidine ER is approved for ADHD at ages 6 to 17, alone or with a stimulant. Moderate or severe sedation in 28% in one trialNICE 1.7.17, 1.8.14 [11]; label [10]; trial, abstract only [23]
Add guanfacine ER or clonidine ER to the stimulantNot in NICE’s list. US labels: approved as adjunctive therapy to stimulants for ADHD (not for tics). AAN: clonidine plus methylphenidate is probably more likely than placebo to reduce both tic severity and ADHD symptoms, and alpha-2 agonists may benefit both conditions. In one trial, tic scores improved 11.0 points more than placebo on the combination, the same as on methylphenidate alone (11.0) and similar to clonidine alone (10.9); the combination’s added benefit was for ADHD symptoms (teacher-rated, 6.3 points over placebo against 3.3 for each drug alone). This evidence is for clonidine with methylphenidate; we found none for guanfacine ER as an add-on in children with ticsLabels [9][10]; AAN ADHD rationale and 8a [16]; trial via Cochrane [19]
Stop medicationAn option when tics outweigh the benefitNICE 1.8.14 [11]
The detail: what each option involves

NICE lists these options: reduce the stimulant dose, or consider changing to guanfacine (in children aged 5 years and over and young people only), atomoxetine (off-label use for adults with no ADHD symptoms in childhood), clonidine (off-label use for children), or stopping medication; clonidine should only be considered for people under 18 after advice from a tertiary ADHD service [11]. In a 16-week trial in 136 children with ADHD and a chronic tic disorder, worse tics were reported as often on methylphenidate (20%) as on clonidine (26%) or placebo (22%); and 28% on clonidine reported moderate or severe sedation (abstract only) [23]. The Cochrane review reports similar improvements in tic scores over placebo with methylphenidate (11.0 points), clonidine (10.9) and both (11.0); tics limited further dose increases in 35% on methylphenidate alone against 15% to 19% in the other groups; and the mean methylphenidate dose, about 26 mg a day, was at the lower end of clinical practice [19]. In 34 medication-free children with ADHD and a tic disorder, guanfacine (1.5 to 3 mg a day in three divided doses, 8 weeks) improved teacher-rated ADHD scores by 37% against 8% and tic severity by 31% against 0% (abstract only) [20][19]. A small trial of guanfacine extended-release in 34 children with chronic tic disorders did not confirm a clinically meaningful effect on tics (abstract only) [21]; only 50% of the guanfacine group and 22% of the placebo group had ADHD [24]. The AAN counsels that alpha-2 agonists may benefit both tics and ADHD [16]. In the atomoxetine trial, 148 patients aged 7 to 17 with ADHD and Tourette's syndrome (80%) or chronic motor tic disorder (20%) received a flexible 0.5 to 1.5 mg/kg/day (mean 1.3 mg/kg/day); a non-inferiority analysis found atomoxetine did not worsen tics on the Yale Global Tic Severity Scale total score. The label reports that 70% stopped early, most for lack of ADHD effect (50% on atomoxetine and 63% on placebo) [8]. The trial report adds that ADHD scores improved more than on placebo, tic scores fell more (approaching significance on the Yale scale), and discontinuation rates did not differ significantly between groups (abstract only) [25]. European guidelines say a transient increase in tics may occur on stimulants, and suggest atomoxetine as a possible alternative in rare cases with a persistent increase [24]. The Cochrane review notes that dose increases of methylphenidate and dextroamphetamine may be limited by tics [19]. Our view: reduce the dose first and allow several weeks to judge, because tics wax and wane; if a switch or an add-on is needed, change one thing at a time. The AAN asks prescribers to monitor heart rate and blood pressure on guanfacine or clonidine, to monitor QTc on guanfacine ER in patients with cardiac history, another QT-prolonging drug or a family history of long QT, and to taper alpha-2 agonists gradually to avoid rebound hypertension [16] (Chapter 5).

Known tic disorder

NICE says to offer people with ADHD and a tic disorder the same medication choices as other people with ADHD. A Cochrane review found that stimulants have not been shown to worsen tics in most people with tic disorders, though they may in individual cases; the evidence was of low or very low quality. For people with tics who have access to it, the American Academy of Neurology says to offer behavioral therapy (CBIT) as an initial treatment option relative to medication.

QuestionWhat we can sayBasis
Can a child with Tourette's syndrome take a stimulant?NICE: the same medication choices as other people with ADHD. AAN: ensure appropriate ADHD treatment when ADHD is functionally impairingNICE 1.7.18 [11]; AAN 3c [16]
What should be recorded first?Family history and a clinical evaluation for tics; a valid scale may be used to measure tic severityLabels [1][7]; AAN 6a [16]
Treating the tics themselvesBehavioral therapy (CBIT): much or very much improved in 52.5% against 18.5% with supportive therapy; children on stable medication could take partAAN 7b [16]; trial [14]
The detail: treating ADHD when tics are already present

NICE does not ask prescribers to avoid stimulants in people with tic disorders; it says to offer the same medication choices as other people with ADHD [11]. The AAN guideline asks clinicians to assess for ADHD in people with tics and, when ADHD is functionally impairing, to ensure appropriate ADHD treatment is provided [16]. It finds that, in children with tics and ADHD, clonidine, clonidine plus methylphenidate, methylphenidate and guanfacine are probably more likely than placebo to reduce tic severity and ADHD symptoms [16]. A Cochrane review of ADHD medicines in children with tics found low-quality evidence for methylphenidate, atomoxetine and clonidine and very low-quality evidence for the others; tics improved with guanfacine, desipramine, methylphenidate, clonidine and methylphenidate plus clonidine, while high-dose dextroamphetamine appeared to worsen tics in one 3-week study [19]. The European guidelines give first preference to psychoeducation and behavioral approaches for tics [24]. In a randomized trial in 126 children aged 9 to 17 with Tourette's or chronic tic disorder, behavioral therapy (CBIT) reduced the Yale Global Tic Severity Scale total tic score by 7.6 points against 3.5 with supportive therapy, and 52.5% against 18.5% were much or very much improved; children on stable psychotropic medication for tics or allowed disorders, including ADHD, could take part [14]. The Yale Global Tic Severity Scale is clinician rated and covers the number, frequency, intensity, complexity and interference of tics (abstract only) [26]; in the CBIT trial it rated the past week [14]. Our view: record the tic pattern before the first dose, so later changes can be judged against it.

Movements that may not be tics

Our view: tics causing injury, or movements that may be seizures or another movement disorder, need same-day assessment. NICE says to review ADHD medication if seizures are new or worse, and to stop any medication that might be contributing. Rapid onset of complex tic-like movements and sounds in an adolescent may be functional rather than a primary tic disorder. Extra or unaccounted-for doses are also a same-day flag (Chapters 1 and 16).

SignConsiderBasis
Staring or jerking with loss of awarenessSeizureNICE 1.8.16 [11]; convulsion in Daytrana postmarketing reports [4]; our view
Sustained abnormal postures, or movements that are not brief and repeatedAnother movement disorderDyskinesia and extrapyramidal disorder in Daytrana postmarketing reports; dyskinesia in Adderall XR [4][6]; our view
Tics causing injury or painSevere tic disorderAAN [16]; our view
Rapid onset, over hours to days, of complex movements and sounds in an adolescent, mostly girlsFunctional tic-like behaviorsExpert viewpoint [15]
The detail: when it is not a simple tic

NICE says that if a person with ADHD develops new seizures or a worsening of existing seizures, review their ADHD medication and stop any medication that might be contributing; after investigation, cautiously reintroduce ADHD medication if it is unlikely to be the cause [11]. Typical tics are usually brief, rapid movements or sounds, such as blinking or throat clearing, and are commonly preceded by premonitory urges [14]. In primary tic disorders, tics usually begin gradually in early childhood with simple tics, and older children can usually suppress them at least briefly [15]. An expert viewpoint from eight tic clinics described young people aged 12 to 25, almost exclusively girls and women, with rapid onset of complex tic-like behaviors reaching peak severity within hours to days, a relative lack of simple tics, and less effective suppression; these were mostly consistent with a functional neurological disorder, and the authors recommend prompt diagnosis and expert review [15]. Our view: a phone video of the movement, a description of awareness during it, and whether it can be briefly held back are the most useful information to gather. The labels list other movements among postmarketing reports: convulsion, dyskinesia and extrapyramidal disorder for the methylphenidate patch, and dyskinesia for mixed amphetamine salts [4][6]. Misuse or extra doses can also cause abnormal movements (Chapters 1 and 16).

Clinical pearls

  • Record tics before the first dose.Otherwise every later tic looks new.
  • Tics wax and wane.NICE says so; judge over weeks, not days.
  • Tics are common on placebo too.In trials, about as common as on stimulants (abstract only).
  • Weigh tics against benefit.NICE asks which impairs more.
  • Reduce before you switch.One change at a time (our view).
  • Tourette's is not a bar to stimulants.NICE offers the same choices.
  • Clonidine for tics in a child needs tertiary advice.NICE (UK) says so.
  • Not every jerk is a tic.Ask for a video (our view).

Family script & EMR note

Script: a parent notices new blinking

"Tics like this are common in children, with or without medicine, and they often come and go over weeks. The medicine can sometimes bring them on or make them stronger, so we will watch them together.

Could you keep a note of the tics for the next few weeks, and take a short phone video if you can? If they bother [him/her] or get in the way, we can lower the dose or change the medicine.

If a movement causes injury, or [he/she] seems unaware during it, contact us the same day. If [he/she] has what looks like a seizure for the first time, call 911, even if it stops. Also call 911 if a seizure does not stop, seizures keep coming, [he/she] has trouble breathing or waking up, or is badly hurt."

EMR note: copy, paste and edit

TICS ON ADHD MEDICINE

Patient: [ ]   Age: [ ]
Medicine / dose / product: [ ]
Start date / last dose change: [ ]
Tics before treatment: [Y/N]
Family history of tics: [Y/N]
Tic type: [motor / vocal / both]
Severity / interference: [ ]
ADHD benefit: [ ]
Injury or pain: [Y/N]
Possible seizure / other
  movement: [Y/N]
Extra or missing doses: [Y/N]

Plan:
 [ ] Continue and monitor
 [ ] Dose reduced to: [ ]
 [ ] Switched to: [ ]
 [ ] Tertiary advice (clonidine)
 [ ] Review: 2026

Clinician: [ ]   Date: [ ]
Case (hypothetical): the new blinking

A 9-year-old boy with ADHD takes OROS-methylphenidate. Six weeks ago his dose went from 27 mg to 36 mg, and his teacher reports a clear improvement. Four weeks ago he began blinking hard and clearing his throat, worse when tired or excited. The tics do not hurt, and he says other children have not noticed. His father had "twitches" as a child. There was no blinking before treatment, by his parents' account. He has no staring spells, and there are no extra doses.

By the end of this chapter you should be able to say whether to continue, reduce or switch.

Case resolution

NICE asks two questions: are the tics related to the stimulant, and does their impairment outweigh the benefit of treatment [11]? The tics began 2 weeks after a dose increase, which fits a stimulant effect, but tics naturally wax and wane [11], and in placebo-controlled trials new or worse tics were reported about as often on placebo as on stimulants (abstract only) [18]. Blinking and throat clearing are typical simple tics [14], he is approaching the ages at which tic severity usually peaks [16][17], and his father's history suggests a family tendency (our view). The tics do not hurt or interfere, and his ADHD has clearly improved; the AAN, writing about Tourette's and chronic tic disorders, says watchful waiting is acceptable when tics cause no functional impairment [16]; his tics are only 4 weeks old, so applying it here is our extrapolation. Our view: continue the current dose for now, ask the family to log the tics and take a short video, and review in 4 to 6 weeks. If the tics begin to interfere, our first step would be to return to 27 mg, one of NICE’s options [11]; if they still interfere on the lower dose, NICE lists guanfacine, atomoxetine, clonidine after tertiary advice, or stopping [11]. In one trial in children with ADHD and established chronic tic disorders, tics limited further dose increases in 35% on methylphenidate alone against 19% on placebo, while worse tics were reported as an adverse effect in 20% on methylphenidate against 22% on placebo; the Cochrane review describes this as "fear of worsening tics" limiting dose increases [19]. Further increases may be limited (our view). If the tics persist and impair, for people who have access to it, the AAN offers behavioral therapy (CBIT) as an initial option rather than only after medication changes [16], though applying it to tics this new is also our extrapolation; at 9 he is at the lower age limit of the CBIT trial, and the AAN notes little evidence below age 9 [14][16]. In the US, adding guanfacine ER or clonidine ER to the stimulant is another option; they are approved as add-ons for ADHD, not for tics [9][10]. The labels ask for family history and monitoring, and to stop if clinically appropriate [1].

Why it matters

Every stimulant label reviewed here warns about tics [1][7], yet in placebo-controlled trials new or worse tics were reported about as often on placebo (abstract only) [18]. Stopping a helpful stimulant for mild tics that would have come and gone anyway costs the child the benefit of treatment, while missing tics that do follow the dose, or a movement that is not a tic, leaves them impaired or at risk.

References (26)
  1. Concerta (methylphenidate hydrochloride) extended-release tablets [US prescribing information]. Janssen Pharmaceuticals, Inc. Warnings and precautions (5.11) and patient counseling information. Revised April 2026. Accessed October 2026 via DailyMed. Source type: US product label.
  2. Ritalin (methylphenidate hydrochloride) tablets [US prescribing information]. Sandoz Inc. Warnings and precautions (5.10). Revised February 2025. Accessed October 2026 via DailyMed. Source type: US product label.
  3. Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules [US prescribing information]. Novartis Pharmaceuticals Corporation. Warnings and precautions (5.10). Revised September 2025. Accessed October 2026 via DailyMed. Source type: US product label.
  4. Daytrana (methylphenidate transdermal system) [US prescribing information]. Noven Therapeutics, LLC. Warnings and precautions (5.15) and adverse reactions (6.1, Table 2). Revised September 2025. Accessed October 2026 via DailyMed. Source type: US product label.
  5. Adderall (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate) tablets [US prescribing information]. Teva Pharmaceuticals USA, Inc. Warnings and adverse reactions. Revised May 2024. Accessed October 2026 via DailyMed. Source type: US product label.
  6. Adderall XR (mixed amphetamine salts) extended-release capsules [US prescribing information]. Takeda Pharmaceuticals America, Inc. Warnings and precautions (5.9) and adverse reactions (6.2). Revised April 2026. Accessed October 2026 via DailyMed. Source type: US product label.
  7. Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets [US prescribing information]. Takeda Pharmaceuticals America, Inc. Warnings and precautions (5.8), adverse reactions (Table 1) and patient counseling information. Revised April 2026. Accessed October 2026 via DailyMed. Source type: US product label.
  8. Strattera (atomoxetine) capsules [US prescribing information]. Eli Lilly and Company. Adverse reactions (6.2) and clinical studies (14.3). Revised June 2026. Accessed October 2026 via DailyMed. Source type: US product label.
  9. Intuniv (guanfacine) extended-release tablets [US prescribing information]. Takeda Pharmaceuticals America, Inc. Full label searched for tics. Revised June 2025. Accessed October 2026 via DailyMed. Source type: US product label.
  10. Clonidine hydrochloride extended-release tablets [US prescribing information]. Actavis Pharma, Inc. Full label searched for tics. Revised October 2023. Accessed October 2026 via DailyMed. Source type: US product label (generic twice-daily ADHD tablet).
  11. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline NG87. Published March 2018; last updated September 2019. Recommendations 1.7.17, 1.7.18, 1.8.13, 1.8.14 and 1.8.16 read. Accessed October 2026. Source type: UK national clinical guideline.
  12. Qelbree (viloxazine) extended-release capsules [US prescribing information]. Supernus Pharmaceuticals, Inc. Full label searched for tics. Prescribing information revised January 2025; DailyMed SPL revised October 2026. Accessed October 2026 via DailyMed. Source type: US product label.
  13. Wolraich ML, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528. doi:10.1542/peds.2019-2528. Key action statement 3 read in full text (PMC7067282). Source type: US clinical practice guideline (American Academy of Pediatrics).
  14. Piacentini J, Woods DW, Scahill L, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA. 2010;303(19):1929–1937. doi:10.1001/jama.2010.607. PMID 20483969. Read in full text (author manuscript, PMC2993317). Source type: randomized controlled trial.
  15. Pringsheim T, Ganos C, McGuire JF, et al. Rapid onset functional tic-like behaviors in young females during the COVID-19 pandemic. Mov Disord. 2021;36(12):2707–2713. doi:10.1002/mds.28778. PMID 34387394. Read in full text (PMC8441698). Source type: expert viewpoint with registry data.
  16. Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):896–906. PMID 31061208. Read in full text (PMC6537133). Source type: clinical practice guideline (American Academy of Neurology).
  17. Leckman JF, Zhang H, Vitale A, et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics. 1998;102(1 Pt 1):14–19. doi:10.1542/peds.102.1.14. PMID 9651407. Abstract only. Source type: cohort study (36 patients).
  18. Cohen SC, Mulqueen JM, Ferracioli-Oda E, et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2015;54(9):728–736. doi:10.1016/j.jaac.2015.06.011. PMID 26299294. Abstract only. Source type: meta-analysis of randomized controlled trials.
  19. Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018;6(6):CD007990. doi:10.1002/14651858.CD007990.pub3. PMID 29944175. Read in full text (PMC6513283). Source type: Cochrane systematic review.
  20. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067–1074. PMID 11431228. Abstract only. Source type: randomized controlled trial.
  21. Murphy TK, Fernandez TV, Coffey BJ, et al. Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. J Child Adolesc Psychopharmacol. 2017;27(9):762–770. PMID 28723227. Abstract only. Source type: randomized controlled pilot trial.
  22. Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 1999;38(8):944–951. doi:10.1097/00004583-199908000-00009. PMID 10434485. Abstract only. Source type: randomized controlled trial.
  23. Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58(4):527–536. PMID 11865128. Abstract only. Source type: randomized controlled trial.
  24. Roessner V, Eichele H, Stern JS, et al. European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry. 2022;31(3):425–441. PMID 34757514. Read in full text (PMC8940878). Source type: European clinical guideline.
  25. Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65(12):1941–1949. PMID 16380617. Abstract only. Source type: randomized controlled trial.
  26. Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989;28(4):566–573. doi:10.1097/00004583-198907000-00015. PMID 2768151. Abstract only. Source type: scale validation study.

Last reviewed October 2026. Part of the Psychiatry Education Forum Academy, Managing ADHD Medication Adverse Events · Section 2 · Chapter 11.

This chapter is educational material for licensed prescribers and prescribers in training. It is not a substitute for clinical judgment, local protocols or the current prescribing information. Psychiatry Education Forum Academy is not a CME provider and this chapter does not carry CME credit.

Responses

Your email address will not be published. Required fields are marked *